Search research articles

Search research articles

Related Experiment Videos

Regulatory processes and three Rs alternatives.

¹Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. milstienj@who.int

Developments in Biologicals

|April 8, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Validation of alternative methods for the potency testing of vaccines.

Alternatives to laboratory animals : ATLA·2015

Same author

Implementation of three Rs methods in 3rd World countries.

Developments in biologicals·2003

Same author

Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test.

Vaccine·2001

Same author

Vaccine vial monitors.

Indian pediatrics·2001

Same author

Invited commentary: stopping polio immunization.

American journal of epidemiology·2001

Same author

Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·1999

Same journal

Review of Ebola virus infections in domestic animals.

Developments in biologicals·2013

Same journal

Ebola: facing a new transboundary animal disease?

Developments in biologicals·2013

Same journal

Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the American mainland.

Developments in biologicals·2013

Same journal

Q fever diagnosis and control in domestic ruminants.

Developments in biologicals·2013

Same journal

Schmallenberg virus.

Developments in biologicals·2013

Same journal

Classical swine fever.

Developments in biologicals·2013

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Laboratory testing for vaccine quality is evolving, shifting from animal safety tests to enhanced manufacturing controls and clinical data. Future regulations aim to reduce animal testing through refinement and replacement strategies.

Area of Science:

Biotechnology
Regulatory Science
Vaccinology

Background:

Historically, laboratory animal testing was central to vaccine quality assurance, predicting human efficacy and safety.
Regulation of biological products relied on inherently variable biological tests due to product variability.

Purpose of the Study:

To examine the evolving concepts in the regulation of vaccines and biological products.
To discuss the shift from traditional laboratory testing towards modern quality assurance systems.

Main Methods:

Review of historical and current regulatory practices for biological products.
Analysis of the impact of product changes and advancements in testing methodologies.
Consideration of Good Manufacturing Practice (GMP) and post-marketing surveillance.

Related Experiment Videos

Main Results:

Regulatory paradigms are shifting towards ensuring product consistency through robust manufacturing processes.
Clinical experience and large post-marketing studies are increasingly vital for safety assessment.
Laboratory tests are becoming more focused on confirming consistency, especially when direct correlates of efficacy are absent.

Conclusions:

Future regulation of biological products will likely involve the replacement, reduction, and refinement (3Rs) of animal testing.
Advancements in product characterization allow for more physical and quantitative tests.
A combination of manufacturing controls, clinical data, and refined laboratory testing will ensure vaccine quality and safety.